News
KZIA
0.3760
+8.61%
0.0298
BRIEF-Kazia Therapeutics Entered Into Purchase Agreement With Alumni Capital
Reuters · 6h ago
Kazia Therapeutics Ltd Entered Into Purchase Agreement With Alumni Capital LP; Pursuant To Purchase Agreement, May Sell To Alumni Capital Up To $15M Of American Depositary Shares From Time To Time
Benzinga · 7h ago
Weekly Report: what happened at KZIA last week (0408-0412)?
Weekly Report · 4d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is the final day of trading this week. PaxMedica stock is rocketing close to 82% after hitting a key milestone in drug development. The biggest pre-market stock movers this morning are earnings reports, stakeholder updates, drug development news and more.
Investorplace · 04/12 11:29
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of NextPlat Corp rose sharply in today’s pre-market trading. The company reported consolidated 2023 revenues of $37.8 million, up 222% year over year. Rent the Runway shares jumped 162% on Thursday after the company reported mixed fourth-quarter financial results.
Benzinga · 04/12 09:32
Weekly Report: what happened at KZIA last week (0401-0405)?
Weekly Report · 04/08 10:30
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Byrna Technologies shares jumped 7.1% to $14.74 on Friday. The company reported better-than-expected first-quarter revenue and announced a CFO transition. MediaCo Holding Inc. Shares jumped 141.7% in today's mid-day session.
Benzinga · 04/05 17:06
Weekly Report: what happened at KZIA last week (0325-0329)?
Weekly Report · 04/01 10:29
Weekly Report: what happened at KZIA last week (0318-0322)?
Weekly Report · 03/25 10:31
Weekly Report: what happened at KZIA last week (0311-0315)?
Weekly Report · 03/18 10:29
Weekly Report: what happened at KZIA last week (0304-0308)?
Weekly Report · 03/11 10:27
Kazia Therapeuti: Correspondence
Press release · 03/05 18:12
Weekly Report: what happened at KZIA last week (0226-0301)?
Weekly Report · 03/04 10:30
Weekly Report: what happened at KZIA last week (0219-0223)?
Weekly Report · 02/26 10:38
12 Health Care Stocks Moving In Friday's Pre-Market Session
Enveric Biosciences (NASDAQ:ENVB) shares increased by 83.5% to $1.56 during Friday's pre-market session. Telesis Bio stock increased by 34.53% and Nexalin Technology stock moved upwards by 19.35%. The company's, Q4 earnings came out yesterday.
Benzinga · 02/23 13:06
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Beneficient stock is rocketing more than 87% with heavy pre-market trading. Intuitive Machines shares are rising over 47% after landing on the moon. The biggest pre- market stock movers for Friday morning are the top 10 biggest gainers. The final day of trading this week.
Investorplace · 02/23 12:30
What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?
Kazia Therapeutics shares are trading lower after initially spiking higher. The stock reached as high as $0.73 during the premarket session. KZIA announced early conclusion of Phase 1 trial of paxalisib in combination with radiation therapy. The study's primary endpoint has been reached, company says.
Benzinga · 02/21 18:58
12 Health Care Stocks Moving In Wednesday's Intraday Session
Emergent BioSolutions (EBS) stock increased by 77.0% to $2.69 during Wednesday's regular session. Ventyx Biosciences (VTYX) shares moved upwards by 72.07%. Motus GI Hldgs (NASDAQ:MOTS) and Iovance Biotherapeutics (IOVA) were also in the spotlight.
Benzinga · 02/21 17:31
Kazia concludes Phase 1 study for paxalisib early due to promising data
Kazia concludes Phase 1 study for paxalisib early due to promising data. The drug was being tested in combination with radiotherapy for the treatment of brain metastases. The FDA granted fast track designation for the therapy last year. Kazia Therapeutics said it has concluded a Phase 1 trial for its drug.
Seeking Alpha · 02/21 15:31
Weekly Report: what happened at KZIA last week (0212-0216)?
Weekly Report · 02/19 10:39
More
Webull provides a variety of real-time KZIA stock news. You can receive the latest news about Kazia Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About KZIA
Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.